JMP Securities Remains a Buy on Rallybio (RLYB)

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Rallybio (RLYBResearch Report) today and set a price target of $29.00. The company’s shares closed last Friday at $9.49.

According to, Wolleben is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.4% and a 34.8% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals.

Rallybio has an analyst consensus of Moderate Buy, with a price target consensus of $29.00.

See today’s best-performing stocks on TipRanks >>

Based on Rallybio’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $14.5 million. In comparison, last year the company had a GAAP net loss of $13.28 million.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RLYB in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Read More on RLYB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More